Fritz Offner

Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial

Purpose of the Study: Duvelisib, a first-in-class oral dual PI3K-, inhibitor, was approved by the FDA for treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/smal...

Julio Delgado ;

Bryone J. Kuss ;

Constantine S. Tam ;

Francesc Bosch ;

Ulrich Jager ;

Paolo Ghia ;

Florence Cymalista ;

Stephan Stilgenbauer ;

Fritz Offner ;

David T. Weaver ;

Stephanie Lustgarten ;

Hagop Youssoufian ;

Ian W. Flinn ;

Nicole Lamanna ;

Marco Montilo ;

Matthew S. Davids , MD, MMSc;

Gabriel Etienne ;

10/22/2019

Characterization of duvelisib in patients with refractory marginal zone lymphoma: data from the phase 2 DYNAMO trial

Purpose of the Study: Duvelisib, a first-in-class oral dual PI3K-, inhibi- tor, was approved by the US FDA for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) o...

Gerardo Musuraca ;

Michele Merli ;

Roberto Marasca ;

David T. Weaver ;

Stephanie Lustgarten ;

Hagop Youssoufian ;

Pier Luigi Zinzani ;

Eric Jacobsen ;

Juraj Ura ;

Kirit Ardeshna ;

Mohamad Cherry ;

Fritz Offner ;